# TMDX — TransMedics Group

## Company & Research Metadata

- **Company:** TransMedics Group
- **Ticker:** TMDX
- **Exchange:** NASDAQ
- **Sector / Industry:** Healthcare / Medical Devices
- **Template version:** 2.7
- **Research date:** 2026-10-21 (comparison refresh; fundamental review preserved from 2026-10-14)
- **Valuation / score price snapshot:** $67.34 — 2026-11-03 regular-session close, America/New_York
- **Tracking tier:** Primary Watchlist
- **Owned:** No
- **Primary operating period reviewed:** Q2 2026 and H1 2026
- **Historical period reviewed:** FY2023–FY2025 plus H1 2026
- **Latest investor presentation reviewed:** September 15, 2026 investor presentation
- **Latest earnings call reviewed:** Q2 2026, August 4, 2026
- **Latest post-earnings management commentary reviewed:** September 10, 2026 CFO announcement

TransMedics is one of the more interesting businesses in medical technology because it is attempting to transform the entire organ-transplant process, rather than simply sell hospitals another medical device.

Its Organ Care System (OCS) preserves and evaluates donor organs, while its National OCS Program (NOP) combines clinical expertise, coordination, and transportation. The opportunity is to make more donated organs usable and improve the efficiency of transplant logistics.

The financial evidence is encouraging, but the business has become more complicated as it expands into aviation and international operations.

In Q2 2026, revenue increased 21% year over year to $189.9 million. Management raised the lower end of its full-year revenue guidance to $737–757 million, representing approximately 22–25% growth.

The central investment question is whether TransMedics can convert its technological lead and integrated logistics network into durable, high-margin cash flows—or whether the costs of building that network will consume more of the economic opportunity than investors expect.

- **Price snapshot date:** 2026-11-03

- **Price snapshot time / timezone:** Regular-session close, America/New_York (including exchange half-days)
- **Competitor / analyst-Q&A audit:** 2026-10-28; original operating, price and valuation snapshots retained.

## What's Changed Since Previous Review

**Current Review:** 2026-10-28

**Previous Review:** 2026-10-21 (comparison refresh; fundamental review preserved from 2026-10-14)

**Update Trigger:** Competitor relevance and analyst-Q&A correction

| Area | Previous View | Current View | Investment Impact |
|---|---|---|---|
| Competition | Preceding operating and comparable-company classifications | Company-specific rivals reviewed; relevant comparisons retained | Corrects the competitive comparison; does not by itself re-underwrite the valuation |
| Analyst questions | Prior source-linked Q&A summaries | Complete questions and sentence-form management answers; all 12 existing rows retained | Improves readability while preserving the recorded exchange meaning |
| Valuation and scores | Approved operating/price snapshots, scenarios, scores and decisions | Preserved | No price refresh, rerank or change to valuation assumptions in this correction pass |

**Thesis:** No new fundamental thesis determination is made in this correction pass. The prior investment decision is preserved; the corrected competitive scope should govern the next substantive review.

## Investment Snapshot

| Metric | Current View |
|---|---|
| Price Snapshot | $67.34 — 2026-11-03 regular-session close, America/New_York |
| Rating / Zone Status | Buy |
| Bear / Base / Bull Fair Value | $43.00 / $84.00 / $148.00 |
| Scenario Probabilities | 30% / 50% / 20% |
| Probability-Weighted Fair Value | $84.50 |
| Probability-Weighted Expected Return | +25.5% |
| Bear-Case Return | -36.1% |
| Strong Buy Zone | ≤ $47.30 |
| Buy Zone | >$47.30–$67.60 |
| Avoid Chasing Above | > $93.89 |
| Quality Score / Tier | 72.6 / Tier B |
| Opportunity Score / Rank | 67.1 / #13 of 76 |
| Risk Level | Medium-High |
| Tracking / Ownership | Primary Watchlist / Not Owned |

**Decision rationale:** I would not chase TMDX at $75.26. The business has a compelling growth opportunity, and the current valuation is much more reasonable than a typical high-growth medical technology stock. However, the estimated upside is relatively modest compared with the downside in the bear scenario. I would become more interested below approximately $68, provided the underlying thesis remains intact.

The central reason for the cautious rating is that **revenue growth remains strong while profitability and free-cash-flow conversion have deteriorated**. That is a meaningful issue for a company investing heavily in technology, logistics, and facilities.

## Investment Thesis

TransMedics is building a potentially powerful healthcare infrastructure business around an existing medical-device platform.

Organ transplantation has historically depended on a fragmented sequence of donor identification, organ recovery, cold preservation, transportation, and surgery. TransMedics aims to coordinate more of that sequence through its OCS technology and National OCS Program.

The potential economic advantage is larger than simply selling more disposable sets. TransMedics can earn revenue from technology, clinical services, and transportation while making its solution easier for transplant centers to adopt.

That creates a reinforcing business model: more procedures support a larger logistics network; the larger network makes the service easier to use; broader availability can support additional procedures.

However, this is **not a software-like, asset-light network effect**. Aircraft, clinical specialists, regulatory approvals, and manufacturing capacity require substantial ongoing investment.

### What the Market May Be Mispricing

| Possible mispricing | Investment interpretation |
|---|---|
| Underestimating the integrated logistics advantage | The full platform may create stronger customer relationships than an organ-perfusion device alone |
| Assuming recent margin declines are permanent | Current R&D and international investment may generate meaningful operating leverage at greater scale |
| Assuming revenue growth guarantees higher earnings | Service mix, capital requirements, competition, and clinical investment may keep returns below expectations |
| Treating the kidney pipeline as near-term revenue | OCS Kidney remains a development opportunity rather than a dependable component of the 2026–2028 forecast |

## Business Overview

TransMedics operates through three closely linked capabilities.

| Business component | How it works | Economic importance |
|---|---|---|
| Organ Care System | Devices and disposable sets that perfuse donor organs outside the body | High-margin product revenue |
| National OCS Program | Clinical teams and services coordinating organ recovery and preservation | Makes the technology easier for transplant centers to use |
| Transplant logistics | Aircraft and ground transportation supporting organ movement | Improves reliability, speed, and control of the transplant process |

#### Organ Care System

The OCS uses organ-specific technology to maintain organs in a more physiologically supportive environment outside the body.

TransMedics markets systems for liver, heart, and lung transplantation.

Unlike traditional static cold preservation, the OCS can enable continued perfusion and assessment of certain donor organs. This can support the use of organs that otherwise may have been considered unsuitable or logistically difficult to transplant.

The commercial model relies primarily on **single-use disposables for each procedure**, rather than repeated large capital-equipment sales.

#### National OCS Program

The NOP provides clinical personnel and procurement services alongside the device.

Hospitals may prefer this arrangement because operating and transporting perfusion equipment requires expertise and coordination. Instead of building all those capabilities internally, a transplant center can use TransMedics' integrated service.

This also changes the competitive dynamics. A competing manufacturer must persuade hospitals not only to adopt another device but, potentially, to change the surrounding workflow.

#### Aviation and logistics

The company's latest investor materials describe a network of approximately 20 hubs, 22 aircraft, 140 pilots, and more than 250 clinical specialists.

Owning greater control of transportation can reduce dependence on third parties and allow better scheduling. Utilization is critical, however. Aircraft must fly enough revenue-generating missions to cover crew, maintenance, depreciation, and other operating costs.

A fleet can be a competitive advantage at high utilization and a drag on returns when volumes disappoint.

#### Revenue composition

| Q2 2026 category | Revenue |
|---|---:|
| OCS products | $111.158M |
| Services | $78.790M |

In Q2 2026, product revenue grew approximately 16%, while service revenue grew approximately 29%.

The faster-growing services business provides operational integration but carries lower gross margins. This creates a tension between strategic strength and accounting profitability.

| Q2 2026 business | Gross margin |
|---|---:|
| Products | 77% |
| Services | 35% |
| Combined | 59.6% |

### Business Takeaway

The integration between products and services makes TransMedics more differentiated, but the mix shift toward services prevents the consolidated company from enjoying the full margin profile of its disposable-device business.

## Industry, TAM & Market Share

The industry's growth opportunity is real, but it should be measured carefully.

In 2025, the United States performed 49,064 organ transplants, including 27,573 kidney transplants and 12,344 liver transplants. The overall market has continued expanding, while donor-organ availability and utilization remain important constraints.

Not all these procedures are addressable by TransMedics' current commercial products. In particular, kidney transplantation represents a major future opportunity, but the company's kidney platform is still in development.

The immediately addressable U.S. business is centered on suitable liver, heart, and lung procedures. Actual adoption also depends on reimbursement, clinical evidence, donor type, hospital economics, and whether competing preservation technologies are preferred.

Management has discussed a goal of approximately 10,000 transplants by 2028 using its existing heart, liver, and lung platform, without depending on the kidney product. That is a management objective, not a confirmed demand forecast or a number assumed to be achieved in my base valuation.

### Market-Share Analysis

A consistent, comparable dataset showing transplant procedures performed with each competing preservation system was not available. Accordingly, a market-share percentage table would create false precision.

#### Competitive Scale / Position

| Company / Platform | Primary Position | Relative Scale | Growth Direction | Investment Relevance |
|---|---|---|---|---|
| TransMedics OCS + NOP | Liver, heart, lung | Broad integrated product and service offering | Revenue growing | Full platform including clinical services and logistics |
| OrganOx metra | Liver | Meaningful direct technology competitor, now backed by Terumo | Stronger strategic support | Direct liver-perfusion competitor |
| XVIVO | Especially lung, with broader preservation offerings | Established specialist competitor | Competitive expansion | Differentiated transplant-preservation specialist |
| Paragonix / Getinge | Cold preservation and transport | Competes through different preservation methods and workflows | Expansion under Getinge | Established preservation alternative |
| Traditional cold storage | Multiple organs | Familiar, often less resource-intensive alternative | Persistent | Alternative approach to preservation |

The opportunity is not simply that more Americans will receive transplants. It is also that a greater proportion of existing and potential donor organs may move through more advanced preservation methods.

### Industry Takeaway

There is room for sustained growth, but commercial penetration should not be confused with ownership of the entire transplant market.

## Customer Economics

Transplant centers are the critical customers, although procurement organizations, reimbursement systems, and transportation partners influence adoption.

Traditional metrics such as subscription churn or net revenue retention are not particularly useful here. More relevant measures are transplant volumes, repeat utilization by centers, revenue per procedure, service attachment, aircraft utilization, and gross profit per case.

The customer value proposition involves reducing logistical complexity and potentially expanding the set of donor organs that can be used.

However, customer economics must be evaluated on both sides.

A center may find the integrated service attractive because it saves organizational effort. But payers and hospitals also have incentives to limit procedure-related costs, and preservation systems compete on clinical outcomes as well as economics.

For TransMedics, the most attractive customer relationship is not necessarily the one producing the greatest revenue per case. It is the relationship producing **sustained procedure volume and attractive incremental profit after the cost of clinical services and logistics**.

The Q2 figures demonstrate the distinction: product gross margin was roughly 77%, compared with 35% for services. Growing both components can deepen customer integration while lowering blended gross margin.

### Customer-Economics Takeaway

Customer relationships appear sticky and operationally complex, but the key economic evidence still needs to come from improving volume-driven margins, cash generation, and returns on the growing asset base.

## Competitive Landscape & Moat

### Competitive Landscape

| Competitor | Market Share | Positioning | Advantages vs. Company | Disadvantages vs. Company | Current Direction |
|---|---|---|---|---|---|
| **OrganOx / Terumo** | Not consistently disclosed | Strong liver-perfusion technology | Strong liver-perfusion technology; backing from a large medtech company | Less comprehensive integrated multi-organ U.S. service network | Strengthening |
| **XVIVO** | Not consistently disclosed | Focused transplant-preservation expertise, particularly in lung | Focused transplant-preservation expertise, particularly in lung | Less extensive integrated U.S. aviation and clinical-service infrastructure | Competitive expansion |
| **Paragonix / Getinge** | Not comparable | Established cold-preservation workflows | Established cold-preservation workflows and diversified corporate support | Different preservation capabilities from OCS warm perfusion | Strengthening following acquisition |
| **Traditional cold storage** | No comparable company share | Familiar workflow | Familiar workflow, lower infrastructure requirements | More constrained preservation and assessment capabilities in some settings | Persistent alternative |

Terumo's approximately $1.5 billion acquisition of OrganOx in October 2025 is especially significant. It suggests that major medical technology companies recognize the strategic value of organ preservation. It also means TransMedics faces a well-resourced competitor in liver perfusion, its most important revenue category.

### Moat Assessment

TransMedics' strongest advantages are integrated operations, clinical experience, and its established transplant-center relationships. FDA authorizations and clinical evidence also create meaningful development and adoption barriers.

Yet the moat has limits. Competing perfusion systems exist, and many aspects of transportation and service coordination can be replicated with sufficient capital and time.

Moreover, the integration strategy makes TransMedics operationally complicated. Its moat must be evaluated after accounting for the capital required to maintain it.

**Moat direction: Stable, with the potential to strengthen.** Logistics integration is an important differentiator, but competition is intensifying in liver preservation. I would not assign the company a dominant or unassailable market position.

### Competitive Takeaway

Logistics integration is an important differentiator, but competition is intensifying in liver preservation. The moat has the potential to strengthen, but it must be judged after accounting for the capital required to maintain it.

## Financial Profile

### Historical Financials

Financial reporting periods follow the issuer's fiscal year: completed FY rows plus standalone current-year quarters and cumulative H1/9M for FY2026. Revenue, FCF and SBC are flows; cash is a period-end balance. FCF = operating cash flow minus property/equipment capex from SEC company facts; quarterly FCF after Q1 and any quarterly SBC derived from YTD are visibly marked. Missing values are N/D, not zero. Unit: USD millions. Data extracted from SEC-tagged filings as of 2026-11-07. Company-specific FCF definitions and acquisition effects may require further reconciliation.

| Period | Revenue | Growth | Gross Margin | Operating Margin | FCF | FCF Margin | SBC | Diluted Shares | Cash | Debt |
|---|---:|---:|---:|---:|---:|---:|---:|---:|---:|---:|
| FY2023 | $241.6 | — | 63.8% | −11.9% | −$164.9 | −68.2% | $19.8 | 32.5M | — | — |
| FY2024 | $441.5 | 82.7% | 59.4% | 8.5% | −$80.9 | −18.3% | $33.2 | 35.2M | — | — |
| FY2025 | $605.5 | 37.1% | 59.9% | 17.9% | $133.6 | 22.1% | $36.9 | 40.5M | — | — |
| Q1 FY2026 | $173.933 | N/D | 58.2% | 7.6% | −$12.124 (derived: CFO - capex) | -7.0% | $9.952 | 36.194 | N/D | N/D |
| Q2 FY2026 | $189.948 | N/D | 59.6% | 12.5% | $10.217 (derived: current YTD - prior YTD) | 5.4% | $8.606 (derived: current YTD - prior YTD) | 40.709 | N/D | N/D |
| H1 FY2026 | $363.881 | N/D | 58.9% | 10.2% | −$1.907 (derived: CFO - capex) | -0.5% | $18.558 | 36.004 | N/D | N/D |
| Q3 FY2026 | $203.005 | N/D | 58.5% | 13.9% | $27.604 (derived: current YTD - prior YTD) | 13.6% | $12.597 (derived: current YTD - prior YTD) | 40.833 | N/D | N/D |
| 9M FY2026 | $566.886 | N/D | 58.7% | 11.5% | $25.697 (derived: CFO - capex) | 4.5% | $31.155 | 36.077 | N/D | N/D |

#### Supplemental historical reporting context (retained)

#### Supplemental historical reporting context (retained)

#### Supplemental historical reporting context (retained)

Diluted weighted-average shares can vary significantly with the accounting treatment of convertible securities; these figures are not a simple chronology of actual shares outstanding.

#### Revenue growth has slowed, but remains substantial

| Period | Annual revenue growth |
|---|---:|
| FY2024 | 82.7% |
| FY2025 | 37.1% |
| 2026E, guidance midpoint | 23.4% |

Management's 2026 revenue guidance of $737–757 million implies continued growth, though at a much lower percentage than in prior years.

Growth slowing with increasing scale is not inherently concerning. What matters is the simultaneous deterioration in profits and cash generation.

#### Profitability and cash conversion

The latest reported quarter illustrates the concern.

| Metric | Q2 2025 | Q2 2026 | Change |
|---|---:|---:|---|
| Revenue | $157.4M | $189.9M | +20.7% |
| Operating income | $36.6M | $23.7M | −35.1% |
| Operating margin | 23.2% | 12.5% | −10.7 pp |
| Net income | $34.9M | $14.7M | −57.9% |
| R&D / clinical expenses | $15.9M | $31.6M | +98.5% |

R&D nearly doubled, particularly because of next-generation technology and clinical-development programs. Some of that spending is intended to support future products.

But that does not make it economically irrelevant. If similar spending recurs as the company continually expands its product portfolio, its effect on profits should not be treated as temporary.

The six-month cash flow is similarly concerning: operating cash flow fell from $88.8 million to $41.8 million year over year, while capital expenditure rose from $36.1 million to $43.7 million.

That left H1 2026 free cash flow slightly negative, compared with positive $52.6 million in H1 2025. Working-capital investment, including receivables and inventory, contributed to the deterioration.

A separate issue affects comparisons with FY2025: the company reported $190.3 million in net income that year, including a $103.3 million benefit from releasing a deferred-tax valuation allowance. Consequently, a simple P/E ratio based on FY2025 earnings overstates the underlying recurring earnings power.

#### Balance sheet and capital intensity

As of June 30, 2026:

| Balance-sheet item | Amount |
|---|---:|
| Cash | $472.7M |
| Convertible notes, principal | $460M |
| Other term debt, approximate principal | $60M |
| Headquarters finance-lease liability | $347.7M |
| Net debt, including finance lease | Approximately $395M |

A critical detail is the headquarters commitment. The $347.7 million finance-lease liability relates to the Somerville headquarters property, **not the aviation fleet**.

Management also estimated approximately $200–240 million of headquarters-related capital expenditures over multiple years through 2030. The lease includes a purchase option with a $374.6 million price if exercised by December 31, 2027.

The purchase obligation is already reflected in the finance-lease liability and should not be added again mechanically to enterprise value. Nevertheless, the related cash funding and additional facility buildout materially complicate future liquidity and free-cash-flow forecasts.

### Financial Takeaways

**Financial direction: Mixed to deteriorating.** Revenue growth remains strong, but margins, cash conversion, and capital intensity currently prevent a higher financial-quality assessment.

## Management & Capital Allocation

Founder and CEO Waleed Hassanein has overseen the transformation of TransMedics from a device-focused business into an integrated transplant platform.

The expansion into logistics was initially a difficult strategic decision because it required moving beyond conventional medical-device economics. The resulting network has become a meaningful commercial differentiator.

Management deserves credit for executing that strategy and scaling annual revenue from approximately $242 million in 2023 to more than $605 million in 2025.

However, two issues deserve scrutiny.

First, capital allocation has become more ambitious. New products, clinical studies, international expansion, aviation, and headquarters development are all competing for resources. The company must demonstrate that these initiatives create sufficient incremental returns.

Second, governance and financial controls require improvement.

The June 2026 Form 10-Q reported a **material weakness in internal control over financial reporting related to inventory movement**. Management had introduced additional controls, but the weakness was not considered remediated as of that filing. This is not evidence that the reported financial statements were misstated, but it reduces confidence in operational controls as the company scales.

TransMedics also appointed Fernando Araujo CFO effective September 21, 2026, succeeding Gerardo Hernandez. A transition during this period of increasing organizational complexity adds an important execution variable.

### Management Takeaway

**Management assessment:** Strong strategic execution history; more mixed capital-allocation and governance assessment. The next phase must demonstrate discipline, not just ambition.

## Valuation

### Current Valuation

| Metric | Value |
|---|---:|
| Price Snapshot | $67.34 — 2026-11-03 regular-session close, America/New_York |
| Market Capitalization | $2.61B |
| Enterprise Value | $3.01B including headquarters finance lease |
| EV / 2026 Guided Sales | 4.0× |
| EV / TTM Sales | 4.5× |
| 2026 Revenue Guidance Midpoint | $747M |

Market capitalization uses approximately 34.68 million shares. The enterprise-value bridge includes approximately $395 million of net debt, including the headquarters finance lease.

The quoted EV/sales multiple is reasonable for a business growing more than 20%, but it does not by itself establish a bargain. The ultimate multiple depends on whether consolidated margins and free cash flow recover.

Only the price row is refreshed here. Other quoted valuation statistics retain their earlier source dates and definitions.

### Comparable Company Analysis

| Company | Relevance | Public / Private | EV / TTM Sales | EV / 2026 Guided Sales | Growth / Margin / Risk Context |
|---|---|---|---:|---:|---|
| **TransMedics** | Subject company | Public | ~4.5× | ~4.0× | Integrated organ technology and logistics |
| **XVIVO Perfusion** | Direct organ-preservation competitor | Public | ~7.4× | N/A | Smaller specialist with a different product and earnings mix |
| **OrganOx** | Direct liver-perfusion competitor | Subsidiary of public Terumo | N/A | N/A | Relevant operating peer, but no standalone public trading multiple |
| **Terumo** | Parent of OrganOx | Public | ~2.9× | N/A | Diversified medtech; secondary valuation anchor |
| **Getinge** | Parent of Paragonix | Public | ~2.3× | N/A | Diversified medtech; secondary valuation anchor |

XVIVO trades at a higher sales multiple, but differences in size, profitability, growth expectations, asset intensity, and product mix matter. I would not mechanically apply XVIVO's multiple to TransMedics.

Similarly, the diversified parent-company multiples for Terumo and Getinge are not clean valuations of their transplant-preservation businesses.

The peer comparison therefore provides context rather than a definitive fair-value answer.

### Valuation Scenarios

My primary approach uses a 2028 revenue estimate and an illustrative terminal enterprise-value-to-sales multiple, discounted to October 2026 at approximately 12% annually.

The framework assumes approximately 35.2 million future shares for the equity bridge and approximately $395 million of net debt, including the finance lease. It treats the convertible-note principal as debt rather than also adding the full potential conversion shares. Share dilution, capped-call effects, and changes in net debt require closer modeling as maturity approaches.

| Scenario | Key Assumptions | Fair Value | Probability | Probability Rationale | Return From Price Snapshot |
|---|---|---:|---:|---|---:|
| **Bear** | ~$830M revenue in 2028, ~2.8× EV/sales; weaker adoption and profitability | $43 | 30% | Material downside does not require commercial failure; slower growth, capital needs, and lower multiple could disappoint | -36.1% |
| **Base** | ~$1.10B revenue in 2028, ~3.8× EV/sales; sustained adoption, partial margin recovery | $84 | 50% | Maintains a strong position in current markets without major near-term revenue from OCS Kidney | +24.7% |
| **Bull** | ~$1.30B revenue in 2028, ~5.45× EV/sales; stronger utilization and execution | $148 | 20% | Requires strong adoption, improving unit economics, and confidence in sustainable margins | +119.8% |
| **Probability-Weighted** | 30% × $43 + 50% × $84 + 20% × $148 | **$84.50** | **100%** | Scenario-weighted modeled value | +25.5% |

Values are rounded. These are discounted present-value estimates based on a late-2028 exit valuation, **not 12-month stock-price targets**.

I assign the bear scenario a substantial 30% probability because meaningful downside does not require commercial failure. Revenue could continue growing while investment needs, competitive pressure, or a lower valuation multiple produce disappointing shareholder returns.

The base scenario assumes that TransMedics maintains a strong position in its current markets without requiring major near-term revenue from OCS Kidney.

The bull scenario requires strong adoption, improving unit economics, and confidence that the integrated operating model can produce attractive sustainable margins.

A significant limitation is that the model holds net debt approximately constant rather than forecasting every headquarters cash outflow, aircraft investment, share issuance, and financing decision through 2028. Additional capital requirements would lower fair value; stronger-than-modeled cash accumulation could raise it. That uncertainty supports the conservative rating.

### Valuation Takeaway

- **Primary valuation method:** Discounted 2028 EV/sales scenario valuation.
- **Cross-check methods:** Current EV/sales, specialist competitor valuation, and historical cash generation.
- **Key valuation dependencies:** Future organ adoption, utilization, product-service mix, sustained margins, capital spending, dilution, and net debt.
- **Valuation confidence / Risk Level:** Medium-high risk.
- **Margin-of-safety conclusion:** Insufficient at the analyzed market price.

The stock does not need a collapse in the transplant business to produce a poor investment outcome. A continuation of revenue growth alongside weak free-cash-flow conversion could be enough.

## Analyst Questions

The August 4, 2026 earnings call contained a broad set of questions about service growth, clinical trial delays, international expansion, regulatory developments, and profitability. The table below covers the material exchanges from the call rather than only a few favorable examples.

| Analyst / Firm | Core Question | Management Response | Research Read-Through |
|---|---|---|---|
| Allen Gong / JPMorgan | Why did service revenue outgrow product revenue? Were dry runs increasing? | Management emphasized logistics and service adoption; CEO initially rejected increasing dry-run rates. | Service growth is encouraging, but transparency around procedure mix matters. |
| Josh Jennings / TD Cowen | What do strong July activity, Q3 seasonality, and CHOPS timing imply? | Management cited seasonal patterns and an anticipated 2027 regulatory path for CHOPS. | Quarterly growth may be uneven; CHOPS timing is uncertain. |
| Bill Plovanic / Canaccord | How are donor screening and delayed clinical studies progressing? | Screening remains early; trial timing depends on FDA processes. | Pipeline execution should not be assumed to proceed on management's preferred timetable. |
| Matthew Mardula / William Blair | When could ENHANCE Heart and DENOVO Lung accelerate? How broad is European reimbursement? | ENHANCE Part A could finish in 2026, while Part B and DENOVO remained constrained. Management clarified that new budget progress specifically concerned Italy. | Regulatory and European adoption expectations require caution. |
| Sam for Matt O'Brien / Piper Sandler | Could changes to organ procurement organization rules create an opportunity? How does logistics scale? | CMS decisions remained pending; management sees operational benefits from greater fleet utilization. | Regulatory upside is optional, not fundamental to the base thesis. |
| Patrick Wood / UBS | Why establish PAD Aviation in Germany, and how does this relate to commercialization? | Germany provides logistical positioning; lack of reimbursement limits local transplant commercialization. | Geographic logistics expansion is not the same as revenue-generating market entry. |
| Daniel Markowitz / Evercore ISI | How quickly can European tenders and the PAD initiative affect revenue? | Management described commercial opportunities but offered limited financial detail. | International forecasts have low near-term visibility. |
| Young Li / Jefferies | What is the impact of organ procurement regulatory reform? | Management emphasized the uncertainty of CMS decisions and continued reliance on its own execution. | External regulatory changes should not be the principal investment thesis. |
| Suraj Kalia / Oppenheimer | Is the 10,000-transplant goal dependent on kidney or future technology? | Management said the goal relies on the existing heart, lung, and liver platform. | Encouraging if achievable, but still a demanding operational target. |
| Mike Matson / Needham | What capabilities does PAD Aviation add? | Management emphasized licensed aviation capacity and additional pilots, with integration over time. | Logistics capacity is expanding ahead of fully demonstrated utilization. |
| David Rescott / Baird | How do service revenue, dry runs, and margins relate? | Management acknowledged possible dry-run differences; CFO warned Q2 service margins would moderate. | The Q2 service-margin level should not be extrapolated indefinitely. |
| Tom Stephan / Stifel | What should investors assume for 2027 operating margins and earnings? | Management declined specific guidance, noting clinical investment could shift into 2027. | Earnings visibility is materially weaker than revenue visibility. |

### Analyst-Q&A Takeaway

Three observations stand out.

First, management is more confident discussing market adoption and revenue expansion than near-term operating margins.

Second, several pipeline and international initiatives remain dependent on regulatory or administrative milestones that the company does not fully control.

Third, the exchange about dry runs and service revenue highlights the importance of understanding the relationship between reported growth and underlying transplant procedures.

The call strengthened confidence in commercial ambition, but it did not resolve concerns about earnings conversion or execution timelines.

## Thesis Monitoring

| Driver | Current State | Positive Trigger / Catalyst | Negative Trigger / Falsifier | What It Changes |
|---|---|---|---|---|
| Organ utilization | Strong revenue growth | Sustained case growth across multiple organs | Stalling adoption or loss of major transplant centers | Growth estimates and moat |
| Service profitability | Q2 improvement, but management expects normalization | Higher utilization produces sustained service-margin gains | Margin falls despite rising volumes | Base-case earnings |
| Liver competition | OrganOx now backed by Terumo | Sustained OCS adoption and clinical differentiation | Competitive wins displace OCS procedures | Revenue and valuation multiple |
| Clinical pipeline | Delays in key clinical programs | FDA progress and accelerating enrollment | Extended delays or unfavorable clinical data | Long-term TAM |
| Free cash flow | Negative in H1 2026 | Strong recovery and lower working-capital needs | Continued cash consumption with higher capex | Valuation confidence |
| Headquarters spending | Significant multiyear commitment | Spending stays within budget and strengthens capacity | Cost overruns or additional financing | Balance-sheet and per-share value |
| Internal controls | Inventory-related material weakness | Verified remediation | Continued or expanded control deficiencies | Quality and governance scores |
| International expansion | Early investment and reimbursement development | Repeatable profitable revenue outside the U.S. | Delayed reimbursement or low utilization | Bull-case probability |

## Quality & Opportunity Scorecards

### Quality Score

| Component | Score | Weight | Weighted Contribution | Evidence |
|---|---:|---:|---:|---|
| Business durability and economics | 75 | 25% | 18.75 | Established OCS and NOP model, but service and capital intensity |
| Moat and competitive position | 79 | 25% | 19.75 | Integrated logistics and clinical services; competition in perfusion |
| Growth runway and durability | 85 | 20% | 17.00 | Potential to increase use of donor organs and expand utilization |
| Financial quality and balance sheet | 56 | 15% | 8.40 | Margins, FCF deterioration, lease and other capital requirements |
| Management, governance and capital allocation | 58 | 15% | 8.70 | Strong strategic execution; control weakness and spending concerns |
| **Quality Score** | **72.6** | **100%** | **72.60** | **Tier B** |

- **Quality Tier:** B
- **Speculative override:** None.

The relatively strong growth and competitive scores reflect the value of the integrated platform and organ-transplant market opportunity.

Financial and governance scores are lower because of recent margin deterioration, weakened cash generation, significant capital requirements, and the unresolved internal-control weakness.

### Opportunity Score

| Component | Raw Input | Normalized Score | Weight | Weighted Contribution |
|---|---|---|---|---|
| Quality | 72.6 | 72.6 | 30% | 21.8 |
| Probability-weighted upside | +25.5% | 100.0 | 35% | 35.0 |
| Bear-case downside | -36.1% | 13.9 | 20% | 2.8 |
| Risk / valuation confidence | 50 | 50.0 | 15% | 7.5 |
| **Opportunity Score** |  | **67.1** | **100%** | **67.1** |

- **Opportunity Rank:** #13 of 76
- **Zone Status:** Buy

## Portfolio Context

- **Tracking tier:** Primary Watchlist
- **Owned:** No
- **Tracking source of truth:** `my_watchlist.md`
- **Portfolio source of truth:** `portfolio/holdings.md`
- **Scoring independence:** Ownership, position size, and cost basis have not influenced the scores or valuation.

TransMedics is already listed in the Primary Watchlist, with ownership marked **No**. Its research file was previously missing.

## Investment Decision History

| Timestamp | Price | Rating | Zone Status | Buy Zone | Strong Buy Zone | Avoid Chasing Above | Base FV | P/W FV | P/W Return | Quality | Opportunity / Rank | Change / Rationale |
|---|---:|---|---|---|---|---|---|---:|---:|---:|---:|---|---|
| 2026-10-14 13:23 ET | $75.26 | Hold / Watch | Hold / Watch | $47.30–$67.60 | ≤ $47.30 | $93.89 | $84 | $84.50 | +12.3% | 72.6 | 56.8 / Pending | Initial research assessment; no previous valuation history available |
| 2026-10-21 (America/New_York) | $74.75 | Hold / Watch | Hold / Watch | >$47.30–$67.60 | ≤ $47.30 | > $93.89 | $84.00 | $84.50 | +13.0% | 72.6 | 57.4 / #27 | Common close and shared-universe rank; prior fundamental assumptions and zones preserved |

###### Final Investment Assessment

TransMedics offers an unusually attractive combination of technological differentiation, an established commercial business, and a meaningful opportunity to expand organ transplantation.

Its strongest feature is not the OCS device alone but the relationship between the device, clinical services, and logistics. Together, they could create a durable infrastructure advantage.

The principal concern is that **commercial success has not yet translated consistently into economic success for shareholders**. The company is generating substantial revenue, but recent financial results show the cost of maintaining and expanding its operating model.

At approximately $75 per share, I believe a reasonable amount of business success is already reflected in the price. Investors are not being compensated sufficiently for the possibility of continued margin pressure, significant capital expenditure, and slower-than-expected earnings growth.

My current rating is **Hold / Watch**, with a probability-weighted fair value of **$84.50** and a preferred purchase range below approximately **$68**.

---

## Material Sources

| Source | Type | Date / Period | What It Supports |
|---|---|---|---|
| [TransMedics 2025 Form 10-K](https://www.sec.gov/Archives/edgar/data/1756262/000119312526067032/tmdx-20251231.htm) | Regulatory filing | FY2025 | Business, historical financials, competitive risks, governance |
| [TransMedics Q2 2026 Form 10-Q](https://www.sec.gov/Archives/edgar/data/1756262/000119312526332843/tmdx-20260630.htm) | Regulatory filing | June 2026 | Financials, debt, leases, controls, capital commitments |
| [Q2 2026 Earnings Release](https://transmedicsinc.gcs-web.com/news-releases/news-release-details/transmedics-reports-second-quarter-2026-financial-results) | Company IR | August 4, 2026 | Results and guidance |
| [Q2 2026 Earnings Call](https://stockanalysis.com/stocks/tmdx/transcripts/661016-q2-2026/) | Earnings-call transcript | August 4, 2026 | Strategy, margins, complete material analyst Q&A |
| [Investor Presentations](https://investors.transmedics.com/presentations) | Company IR | September 15, 2026 | Commercial footprint, roadmap, management objectives |
| [TransMedics Investor Relations](https://investors.transmedics.com/) | Company IR | September 2026 | Management changes and disclosures |
| [UNOS U.S. Transplant Statistics](https://unos.org/media-resources/releases/u-s-surpasses-49000-organ-transplants-while-deceased-organ-donations-dip/) | Industry data | FY2025 | Industry volumes and TAM context |
| [Terumo / OrganOx Acquisition](https://www.terumo.com/newsrelease/detail/20251030/6761) | Competitor corporate release | October 2025 | Competitive position |
| [XVIVO Valuation](https://stockanalysis.com/quote/sto/XVIVO/statistics/) | Market data | October 2026 | Public-company comparison |
| [TMDX Stock Quote](https://stockanalysis.com/stocks/tmdx/) | Market data | October 14, 2026 | Market-price snapshot |
| [TMDX common regular-close snapshot](https://stockanalysis.com/stocks/tmdx/history/) | Market data | 2026-10-20 16:00 EDT | Refreshed price, scenario returns and normalized Opportunity Score / shared rank |
| [SEC XBRL company facts — TMDX](https://data.sec.gov/api/xbrl/companyfacts/CIK0001756262.json) | Regulatory filing (as tagged) | FY2026, through 2026-09-30 | Current-year standalone-quarter and year-to-date source facts for FCF, SBC, revenue and other reported metrics |